(Q34463984)

2 August 2017

title

Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy? (English)

1 reference

2 August 2017

1 reference

4

Mark Emberton

1 reference

2 August 2017

Hashim Uddin Ahmed

1

1 reference

2 August 2017

Manit Arya

series ordinal

2

1 reference

2 August 2017

Alex Freeman

series ordinal

3

1 reference

2 August 2017

publication date

1 November 2012

1 reference

Lancet Oncology Commission

2 August 2017

published in

1 reference

2 August 2017

volume

13

1 reference

2 August 2017

issue

11

1 reference

2 August 2017

page(s)

e509-17

1 reference

A piece of my mind. Making the call

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

1 reference

7 January 2021

Rethinking screening for breast cancer and prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Cancer overdiagnosis and overtreatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Should we really consider Gleason 6 prostate cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Overdiagnosis: An underrecognized cause of confusion and harm in cancer screening.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Controversies in papillary microcarcinoma of the thyroid

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

National Institutes of Health State-of-the-Science Conference statement: Diagnosis and Management of Ductal Carcinoma In Situ September 22-24, 2009.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Active surveillance of renal cortical neoplasms: a contemporary review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Papillary urothelial neoplasm of low malignant potential: evolving terminology and concepts

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Tumor focality in prostate cancer: implications for focal therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Implications of the International Society of Urological Pathology modified Gleason grading system

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Prostate cancer and the Will Rogers phenomenon.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Gleason score 2-4 adenocarcinoma of the prostate on needle biopsy: a diagnosis that should not be made

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Aneusomy of chromosomes 7, 8, and 17 and amplification of HER-2/neu and epidermal growth factor receptor in Gleason score 7 prostate carcinoma: a differential fluorescent in situ hybridization study of Gleason pattern 3 and 4 using tissue microarray

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Multiple mechanisms for p27(Kip1) translocation and degradation.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

A molecular correlate to the Gleason grading system for prostate adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Prognostic relevance of Bcl-2 overexpression in surgically treated prostate cancer is not caused by increased copy number or translocation of the gene

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Integrative molecular concept modeling of prostate cancer progression.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Evolution of the androgen receptor pathway during progression of prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

ERG protein expression reflects hormonal treatment response and is associated with Gleason score and prostate cancer specific mortality

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Angiogenesis in cancer, vascular, rheumatoid and other disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Prognostic value of microvessel density in prostate cancer: a tissue microarray study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

The endocrine-gland-derived vascular endothelial growth factor (EG-VEGF)/prokineticin 1 and 2 and receptor expression in human prostate: Up-regulation of EG-VEGF/prokineticin 1 with malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Vascular pericyte density and angiogenesis associated with adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Development of metastatic and non-metastatic tumor lines from a patient's prostate cancer specimen-identification of a small subpopulation with metastatic potential in the primary tumor.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Regulation of the chemokine receptor CXCR4 by hypoxia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Quantitative tissue analyses of prostate cancer foci in an unselected cystoprostatectomy series

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

The Trade-off Between Sensitivity and Specificity of Clinical Protocols for Identification of Insignificant Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Staging of early prostate cancer: a proposed tumor volume-based prognostic index

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Predicting post-external beam radiation therapy PSA relapse of prostate cancer using pretreatment MRI.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Morphology of prostate cancer: the effects of multifocality on histological grade, tumor volume and capsule penetration.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Asynchronous growth of prostate cancer is reflected by circulating tumor cells delivered from distinct, even small foci, harboring loss of heterozygosity of the PTEN gene.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Is tumor volume an independent prognostic factor in clinically localized prostate cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Some small prostate cancers are nondiploid by nuclear image analysis: correlation of deoxyribonucleic acid ploidy status and pathological features

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

The relationship of TMPRSS2-ERG gene fusion between primary and metastatic prostate cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

ERG rearrangement metastasis patterns in locally advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

The index lesion and the origin of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

The mutational landscape of lethal castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Predicting 15-year prostate cancer specific mortality after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Outcomes of extremely low risk prostate cancer following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

A pathological reassessment of organ-confined, Gleason score 6 prostatic adenocarcinomas that progress after radical prostatectomy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Delayed versus immediate surgical intervention and prostate cancer outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Developing guidelines for chronic kidney disease: we should include all of the outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Outcomes of active surveillance for men with intermediate-risk prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Identifying candidates for active surveillance: an evaluation of the repeat biopsy strategy for men with favorable risk prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Radical prostatectomy versus observation for localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

The Accuracy of Different Biopsy Strategies for the Detection of Clinically Important Prostate Cancer: A Computer Simulation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Is it time to consider a role for MRI before prostate biopsy?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Focal therapy for localized prostate cancer: a phase I/II trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970388-1

7 January 2021

10.1016/S1470-2045(12)70388-1

Identifiers

DOI

1 reference

2 August 2017

1 reference